4 research outputs found
Su1084 Pharmacokinetics of Laquinimod in Patients With Active Moderate to Severe Crohn's Disease
Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
Abstract Background Laquinimod is an oral immunomodulator in clinical development to treat relapsing-remitting multiple sclerosis (RRMS). Laquinimod is in clinical development for the treatment of multiple sclerosis and Huntington Disease (HD). The objective of this study is to assess the safety, tolerability, pharmacokinetics (PK) and cytoimmunologic effects following escalating doses of laquinimod in patients with RRMS. Methods One hundred twelve patients were randomly assigned to laquinimod/placebo in a series of separate dose-escalating cohorts starting from a daily oral dose of 0.9Â mg/1.2Â mg escalating to 2.7Â mg, in 0.3Â mg increments. Results Twenty-eight patients received placebo and 84 received laquinimod ranging from 0.9 to 2.7Â mg. No deaths occurred. One serious adverse event (SAE) of perichondritis was reported, which was unrelated to laquinimod (0.9Â mg). There was no increased incidence of adverse events (AEs) with escalating doses. Laquinimod-treated patients showed more abnormal laboratory levels in liver enzymes, P-amylase, C-reactive protein (CRP), and fibrinogen, but most shifts were clinically non-significant. The exposure of laquinimod was dose proportional and linear in the tested dose range. An immunological substudy showed significant dose-dependent decreases in 6-sulpho LacNAc + dendritic cell (slanDC) frequency following laquinimod compared to placebo. Conclusion Laquinimod doses up to 2.7Â mg were safely administered to patients with RRMS. An in vivo effect of laquinimod on the innate immune system was demonstrated. Trial registration EudraCT Number: 2009-011234-99 . Registered 23 June 2009
Additional file 1: Figure S1. of Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
Study MS-LAQ-101 flow chart. Figure S2. Average plasma concentrations of laquinimod on Day 21 after repeated daily administration. Figure S3. Exposure-dose plots of laquinimod after multiple dose administration. Table S1. Distribution of study drug termination reasons. Table S2. Biochemistry shift analysis to abnormal levels. Table S3. Hematology shift analysis. (DOCX 276 kb